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background: In patients with severe aortic stenosis, TAVR improves survival and quality of life compared with nonsurgical therapy but with 
higher in-hospital costs. Since complications may decrease with greater experience and device iterations, we sought to estimate the impact of 
periprocedural complications on the cost of TAVR.
methods: Using detailed cost data from 406 TAVR pts enrolled in the PARTNER I trial, we developed multivariable models to estimate the 
incremental cost associated with specific periprocedural complications. Attributable costs for each complication were calculated by multiplying the 
independent cost of each event by its frequency in the treatment group.
results: Mean TAVR hospital cost was $78,282 ± 40,790 ($47,322 excluding the valve); 45% of pts had ≥1 complication (Table). Seven 
complications were independently associated with increased hospital costs, with major bleeding and death accounting for the largest attributable 
costs/pt. Renal failure and the need for repeat TAVR, although less frequent, were also associated with increased costs. Overall, complications 
accounted for $8892/pt in initial hospital costs.
conclusion: In the PARTNER trial, periprocedural complications were frequent, costly, and accounted for nearly 20% of non-implant related 
hospital costs. Avoidance of complications should improve the cost-effectiveness of TAVR for inoperable and high-risk pts, but reductions in the cost 
of uncomplicated TAVR will also be necessary for optimal efficiency.
Table. Adjusted incremental hospital costs associated with treating patients with specific complications of TAVR, as obtained from multivariable 
regression models
Complication Frequency of Complication Incremental Cost of Complication 95% CI Attributable Cost
Death 4.9% $42,008 ($25,981 to $58,035) $2,069
Major stroke 3.2% $16,272 (-$1,699 to $34,243) $521
Minor stroke 1.2% *
Major vascular complication 11.6% *
Minor vascular complication 7.9% *
Major bleeding 9.9% $32,869 ($22,010 to $43,728) $3,238
Renal insufficiency 4.2% *
Renal failure 2.2% $68,051 ($46,805 to $89,297) $1,509
Arrhythmia 16.3% $16,067 ($7,366 to $24,768) $514
Permanent pacemaker 3.2% *
Repeat TAVR 0.5% $119,905
($74,311 to 
$165,499)
$591
Surgical AVR 1.7% $26,070 ($1,682 to $50,458) $449
Total cost of complications $8,892
Models adjusted for age, sex, prior bypass surgery, peripheral vascular disease, diabetes, and STS mortality risk score
*These complications were not significantly associated with increased costs in the multivariable model
